Fig. 4: Association of DNADX CN-based signatures associated with CelTIL response after one dose of HER3-DXd. | Nature Communications

Fig. 4: Association of DNADX CN-based signatures associated with CelTIL response after one dose of HER3-DXd.

From: Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

Fig. 4

a Unsupervised hierarchical clustering of 150 CN-based signatures associated with CelTIL response after one dose of HER3-DXd in an unpaired SAM analysis (FDR<10%). b Forest plot of a selection of CN-based signatures significantly associated with CelTIL response after one dose of HER3-DXd in a logistic regression analysis in patients with CelTIL response (n = 16) and without CelTIL response (n = 33). Data are presented as the odds ratios (OR) with error bars showing 95% confidence intervals. Source data are provided as a Source Data file.

Back to article page